Peregrine Sued By Investors Over Cancer Drug Claims

Law360, New York (October 30, 2012, 3:33 PM ET) -- Investors hit Peregrine Pharmaceuticals Inc. with multiple securities class actions last month, alleging that the drugmaker's misleading statements about its lung cancer drug later resulted in a nosedive of the company's stock price.

According to three lawsuits brought in the Central District of California, Peregrine and its top brass violated federal securities laws by issuing materially false statements during the late summer and early fall about the effectiveness of one of its signature products, bavituxmab, which is an experimental drug for the treatment of nonsmall cell...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required

Case Information

Case Title

Dennis W Chew v. Peregrine Pharmaceuticals Inc et al

Case Number

2:12-cv-08380

Court

California Central

Nature of Suit

Securities/Commodities

Judge

Philip S. Gutierrez

Date Filed

September 28, 2012


Case Title

James T Jerie v. Peregrine Pharmaceuticals Inc et al

Case Number

2:12-cv-08400

Court

California Central

Nature of Suit

Securities/Commodities

Judge

Philip S. Gutierrez

Date Filed

September 28, 2012


Case Title

Nathaniel L Anderson v. Peregrine Pharmaceuticals Inc et al

Case Number

8:12-cv-01647

Court

California Central

Nature of Suit

Securities/Commodities

Judge

Philip S. Gutierrez

Law360 Coverage

Date Filed

September 28, 2012

Sections

Law Firms Mentioned

Companies Mentioned

Government Agencies Mentioned

Related Articles